Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 2/20 | 0.65 |
| ▸ | BRD4 | O60885 | 2/20 | 0.65 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.57 |
| ▸ | EGFR | P00533 | 5/20 | 0.53 |
| ▸ | TTK | P33981 | 5/20 | 0.51 |
| ▸ | JAK3 | P52333 | 5/20 | 0.51 |
| ▸ | BTK | Q06187 | 2/20 | 0.51 |
| ▸ | JAK1 | P23458 | 1/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.51 |
| ▸ | AXL | P30530 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3022389 | 0.90 | JAK2 (0.53) | JAK2BRD4PTK2TTKJAK3 | |
| SCHEMBL3018200 | 0.90 | AXL (0.61) | JAK2BRD4PTK2EGFRTTK | |
| SCHEMBL3025146 | 0.89 | BRD4 (0.58) | JAK2BRD4PTK2EGFRJAK3 | |
| SCHEMBL3027137 | 0.88 | AXL (0.63) | JAK2BRD4PTK2EGFRTTK | |
| SCHEMBL3030399 | 0.88 | JAK2 (0.51) | JAK2BRD4PTK2EGFRTTK | |
| SCHEMBL3027514 | 0.86 | BRD4 (0.51) | JAK2BRD4PTK2EGFRJAK3 | |
| SCHEMBL3026156 | 0.86 | TTK (0.62) | JAK2BRD4PTK2TTKBTK | |
| SCHEMBL3026944 | 0.86 | LRRK2 (0.57) | JAK2BRD4PTK2JAK3BTK | |
| SCHEMBL13213035 | 0.85 | PAK4 (0.48) | JAK2BRD4PTK2EGFRJAK3 | |
| SCHEMBL3022745 | 0.82 | EGFR (0.59) | JAK2BRD4PTK2EGFRTTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2393814-A1 | PYRROLOPYRIMIDINYL AXL KINASE INHIBITORS | SuperGen, Inc. (US) | 2011-12-14 | — | — | EP | disclosed |
| US-20100204221-A1 | Pyrrolopyrimidinyl axl kinase inhibitors | TOLERO PHARMACEUTICALS, INC. | 2010-08-12 | — | — | US | disclosed |
| US-20100204221-A1 | Pyrrolopyrimidinyl axl kinase inhibitors | TOLERO PHARMACEUTICALS, INC. | 2010-08-12 | — | — | US | disclosed |
| US-20100204221-A1 | Pyrrolopyrimidinyl axl kinase inhibitors | TOLERO PHARMACEUTICALS, INC. | 2010-08-12 | — | — | US | disclosed |
| WO-2010090764-A1 | PYRROLOPYRIMIDINYL AXL KINASE INHIBITORS | SUPERGEN, INC. (US) | 2010-08-12 | — | — | WO | disclosed |
| WO-2010090764-A1 | PYRROLOPYRIMIDINYL AXL KINASE INHIBITORS | SUPERGEN, INC. (US) | 2010-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204221-A1 | Pyrrolopyrimidinyl axl kinase inhibitors | AXL, FLT3, TYRO3 | JAK2 81/4885BRD4 1521/4885PTK2 59/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.